This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (9)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Rheumatology  • Osteoporosis  • Review  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

An Update

Brett T. Summey, MD; Gil Yosipovitch, MD

Arch Dermatol. 2006;142:82-90.

Objective  To raise awareness of the new treatment options and current recommendations among dermatologists treating patients with systemic corticosteroids.

Data Sources  MEDLINE peer-reviewed publications.

Study Selection  English language and clinical pertinence to corticosteroid-induced osteoporosis.

Data Extraction  Pertinent information on pathophysiologic, epidemiologic, clinical trial, cost-effectiveness, and treatment option data regarding corticosteroid-induced osteoporosis.

Data Synthesis  Comprehensive summary of published data on the pathophysiologic, epidemiologic, clinical, and treatment data and current practice guidelines regarding corticosteroid-induced osteoporosis; creation of an algorithmic management approach for patients treated with long-term oral corticosteroids.

Conclusions  Glucocorticoid-induced bone loss is the most predictable and debilitating complication of prolonged administration of systemic corticosteroids. Every dermatologist prescribing systemic corticosteroids must be aware of corticosteroid-induced osteoporosis and ensure that every patient is receiving general measures to prevent it. Despite efficacious preventive and therapeutic options, actual implementation of these strategies remains unacceptably low. Based on currently available evidence, the first choice for prevention and treatment of glucocorticoid-induced osteoporosis should be a potent oral bisphosphonate such as alendronate (70 mg/wk) or risedronate sodium (35 mg/wk). For patients with severe osteoporosis or patients with active osteoporotic fractures, the anabolic agent teriparatide (recombinant fragmented parathyroid hormone) should be considered as a first-line option for up to 2 years.

Author Affiliations: Departments of Dermatology, Drexel University College of Medicine, Philadelphia, Pa (Dr Summey), and Wake Forest University School of Medicine, Winston-Salem, NC (Dr Yosipovitch).

RELATED ARTICLES

Prevention of Osteoporosis Associated With Chronic Glucocorticoid Therapy
Michael P. Heffernan, Kenneth G. Saag, June K. Robinson, and Jeffrey P. Callen
JAMA. 2006;295(11):1300-1303.
EXTRACT | FULL TEXT  

Cross-sectional Study of Bisphosphonate Use in Dermatology Patients Receiving Long-term Oral Corticosteroid Therapy
Rosemarie H. Liu, Joerg Albrecht, and Victoria P. Werth
Arch Dermatol. 2006;142(1):37-41.
ABSTRACT | FULL TEXT  

The Era of Cooperation
Michael P. Heffernan
Arch Dermatol. 2006;142(1):93-95.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Glucocorticosteroids in football: use and misuse
Dvorak et al.
Br. J. Sports. Med. 2006;40:i48-i54.
ABSTRACT | FULL TEXT  

Prevention of Osteoporosis Associated With Chronic Glucocorticoid Therapy
Heffernan et al.
JAMA 2006;295:1300-1303.
FULL TEXT  

The Era of Cooperation
Heffernan
Arch Dermatol 2006;142:93-95.
FULL TEXT